WuXi Biologics Pays $183 Million to Acquire Bayer German Manufacturing Facility

WuXi Biologics of Shanghai will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany . The German facility will be the 16th manufacturing facility for the company. The 30,000-square-meter facility will include three 1,000-liter perfusion reactors and six 2,000-liter fed-batch reactors. WuXi Bio and Bayer also announced a long-term sublease agreement and transition service contract to manufacture Bayer's Kovaltry, a Hemophilia A therapy, in the facility. More details.... Stock Symbol: (HK: 2269) Share this with colleagues: // //